Pharnext SA - ESG Rating & Company Profile powered by AI
The ESG assessment for Pharnext SA indicates the company's transparency towards the UN Sustainable Development Goals. Complete Sustainability analysis of Pharnext SA can be accessed by signing in. This assessment of Pharnext SA is assembled by All Street Sevva using advanced AI.
Pharnext SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 8.0, social score of 6.4 and governance score of 4.0.
6.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 586 | Traphaco JSC | 6.2 | High |
| 586 | Xenon Pharmaceuticals Inc | 6.2 | High |
| 623 | Pharnext SA | 6.1 | High |
| 623 | Achieve Life Sciences Inc | 6.1 | High |
| 623 | Anatara Lifesciences Ltd | 6.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Pharnext SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Pharnext SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Pharnext SA report the average age of the workforce?
Sign up for free to unlockDoes Pharnext SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Pharnext SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Pharnext SA disclose cybersecurity risks?
Sign up for free to unlockDoes Pharnext SA offer flexible work?
Sign up for free to unlockDoes Pharnext SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Pharnext SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Pharnext SA conduct supply chain audits?
Sign up for free to unlockDoes Pharnext SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Pharnext SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Pharnext SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Pharnext SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Pharnext SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Pharnext SA disclose water use targets?
Sign up for free to unlockDoes Pharnext SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Pharnext SA have a product recall in the last two years?
Sign up for free to unlockDoes Pharnext SA disclose incidents of discrimination?
Sign up for free to unlockDoes Pharnext SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Pharnext SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Pharnext SA disclose parental leave metrics?
Sign up for free to unlockDoes Pharnext SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Pharnext SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Pharnext SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Pharnext SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Pharnext SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Pharnext SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Pharnext SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Pharnext SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Pharnext SA disclose its waste policy?
Sign up for free to unlockDoes Pharnext SA report according to TCFD requirements?
Sign up for free to unlockDoes Pharnext SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Pharnext SA disclose energy use targets?
Sign up for free to unlockDoes Pharnext SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Pharnext SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Pharnext SA
These potential risks are based on the size, segment and geographies of the company.
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.